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Introduction
Tumour suppressor genes are attractive candidates as markers
for early genetic diagnosis because, by definition, their loss
should be followed by switching to a tumorigenic phenotype.
The molecular pathology of pancreatic carcinogenesis is char-
acterized by a broad spectrum of distinct gene mutations and
chromosomal alterations, some of which seem to be non-
random. Recent advances in molecular biology have increased
our understanding of the pathophysiology of, and the fre-
quent genetic alterations in, this disease.1
Functional Analysis of Chromosome 18 in Pancreatic
Cancer: Strong Evidence for New Tumour Suppressor
Genes
Many studies employing different molecular techniques
have consistently outlined the loss of chromosome 18q as an
early event in pancreatic carcinogenesis. Chromosome 18 har-
bours a cluster of either tumour or metastasis suppressor
genes such as SMAD2, SMAD4, DCC, maspin and PAI-2. Loss of
heterozygosity (LOH) of 18q is a common event in more than
90% of pancreatic carcinomas, while only 50% are character-
ized by bi-allelic inactivation of the SMAD4 genes.2,3 This high
frequency of losses affecting 18q caused special interest in this
region. We reported the loss of 18q in 92% of pancreatic juice
samples collected from patients with clinically early pancre-
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atic neoplasia and emphasized this approach as a useful tool in
early detection of this deadly disease.4 In a recent study, we
found that LOH of 18q is significantly associated with a poor
prognosis in pancreatic cancer.5 Loss of SMAD4 expression
occurs biologically late in neoplastic progression; therefore,
even when clinically early infiltrating pancreatic cancers are
detected, they could, in fact, be considered genetically late.6,7
On the other hand, adenovirus-mediated transfection with
SMAD4 inhibits mouse tumorigenesis by halting angiogenesis
but fails to inhibit in vitro growth of pancreatic ductal adeno-
carcinoma cells with completely inactivated SMAD4.8,9
To date, there is no strong evidence that implicates SMAD2
or MADH2, another candidate tumour suppressor gene resid-
ing on chromosome 18q, in colon and other cancers; they are
inactivated only in a small fraction, accounting for 5% of colon
and other cancers.10 Loss of DCC expression was initially
found to be involved in colon cancer,11 where it could play a
role in tumour progression. However, only one recent study
reported inactivation of DCC by homozygous deletions in a
subset of pancreatic and biliary cancers, as an isolated event or
in addition to SMAD4 alterations.12
Maspin is initially expressed in normal human mammary
and prostate epithelial cells, but is down-regulated during
cancer progression. Maspin inhibits cell motility, invasion and
metastasis in breast and prostate cancers.13 Maspin expression
is up-regulated in pancreatic cancer, in contrast to its absence
in normal pancreatic tissue.14,15 However, mutations in these
genes alone cannot explain the whole process of pancreatic
carcinogenesis; there may be some other genes that play im-
portant roles. We have focused on tumour suppressor genes in
pancreatic cancer to find effective methods for genetic diagno-
sis and/or treatment. Given that a few different known and
probably unknown tumour and metastasis suppressor genes
are clustered on 18q, we presumed that correction of these
defects could restore quasi-normal growth status to pancre-
atic cells.
This study was undertaken to provide functional evidence
for the existence of new tumour suppressor genes located on
chromosome 18 that play a role in pancreatic tumorigenesis.
Materials and methods
Cell lines
Two-pancreatic cancer cell lines, PK-1 (established in our
department from liver metastasis of pancreatic cancer)16 and
Panc-1 (American Type Culture Collection, Rockville, MD,
USA), were cultured according to the protocols of the suppliers.
The cell lines are well characterized.17
Briefly, PK-1 is homozygous for deletion of SMAD4
(SMAD4–/–), whereas Panc-1 expresses normal SMAD4
(SMAD4wt) (Table). For each cell line, three stable hybrids
containing a normal copy of chromosome 18 (detected by
fluorescence in situ hybridization, FISH, using mouse DNA as
probes) were established: PK-1H(18)-1 through -3 and Panc-
1H(18)-1 through -3, respectively. These hybrids were gener-
ated by the microcell-mediated chromosome transfer (MMCT)
technique and expanded in medium containing 400 µg/mL
of G418, as previously described.18–20 The A9H(18) mouse
fibroblast cell line, which carries a single copy of human
chromosome 18 and an integrated neomycin resistance gene,
was maintained in the same selective medium. All cells were
routinely monitored for mycoplasma as well as for mouse
hepatitis, Sendai and pneumonia viruses, and were consis-
tently negative.
Table. Oncogenic properties of stable hybrid cells
PK-1 PK-1H(18) Panc-1 Panc-1H(18)
Colony formation (number/3 cm dish)*† 228 ± 19.36 49 ± 3.61 196 ± 18.21 34 ± 2.89
Colony size (µm)*† 392 ± 39.22 106.4 ± 19.61 293 ± 32.93 32 ± 29.66
Apoptosis index (%)†‡ 2.1 ± 0.5 3.9 ± 0.7 1.9 ± 0.3 4.1 ± 0.5
Tumour size (mm3 at day 45)† 1945 ± 245 366 ± 98 756 ± 168 142 ± 39
Latency period (d)†§ 8 ± 2 14 ± 3 9 ± 3 18 ± 3
Lung metastatic lesion (number/lung)†II 51 ± 11.8 5.2 ± 2.6 29 ± 9 6 ± 3.4
Proliferation index (PCNA-positive cells/x 40 field)† 57 ± 11.6 16 ± 5.1 42 ± 8.3 9 ± 3.4
SMAD4 status of parental cells SMAD4–/– SMAD4+/+
*Colony number and size were measured and averaged from three randomly chosen photographs from each plate; †averaged results ±
standard deviation from three independent experiments; ‡apoptotic cells were detected by annexin V/EGFP staining; §latency period is
defined as time course when tumours became palpable (reached 4–5 mm in diameter); IIsurface lung metastatic tumours counted and
microscopically confirmed on day 30. PCNA = proliferating cell nuclear antigen.
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Microsatellite analysis
Genomic DNA from cells and nude mouse tumours was ex-
tracted using the Nucleon BACC3/ST kit (Amersham Bio-
sciences UK Limited, Little Chalfont, Buckinghamshire, En-
gland) and analysed using highly polymorphic microsatel-
lite markers located on 18q, as described previously.20,21
Briefly, seven microsatellite markers, D18S1104, D18S463,
D18S72, D18S35, D18S1144, D18S483 and D18S58 (http://
gdbwww.gdb.org), are spaced at approximately 10 cM inter-
vals (mean, 9.96 cM) along the long arm of chromosome 18.
Microsatellite primers were designed to amplify approximately
100 bp to 150 bp products. The forward primers of each pair
were end-labelled with 32P-g-ATP using T4 polynucleotide
kinase (New England Biolabs, Beverly, MA, USA). Polymerase
chain reaction (PCR) amplification consisted of initial dena-
turation at 95°C for 2 minutes, 40 cycles consisting of dena-
turation at 95°C for 30 seconds, annealing at 60–62°C for 30
seconds, and extension at 72°C for 30 seconds, followed by a
final extension at 72°C for 5 minutes. The PCR products were
separated in 8 M urea-polyacrylamide gel and autoradio-
graphed. For each marker, PCR amplification was carried out
at least twice.
In vitro proliferation
Anchorage-dependent proliferation was monitored using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay for 5 days, in the absence of G418, and a daily
proliferation index (PI) was calculated for each parental and
corresponding hybrid cell line.22 Conversion of MTT to for-
mazan dye was measured using absorbance at 590 nm in a
multi-well plate immunoreader system. Data from three inde-
pendent experiments were pooled, averaged and analysed.
Colony formation assay
Ten thousand cells were plated in 1 mL medium contain-
ing 0.3% Bacto-agar (Becton Dickinson, Sparks, MD, USA)
with 10% fetal bovine serum as an upper layer into 30 mm
dishes. Another 1 mL medium with 0.7% Bacto-agar was used
for the bottom layer. After 2 weeks, viable colonies were stained
red by incubation for 3 hours with 0.3 mL of 1 mg/mL 2-[4-
iodophenyl]-3-[4-nitrophenyl]-5-phenyl-2H-tetrazolium chlo-
ride (INT; Dojindo Laboratories, Kumamoto, Japan). Red
colonies were photographed using a Zeiss microscope (Carl
Zeiss, Jena, Germany) with × 5 objective. Both the number and
size of colonies were measured and averaged on three ran-
domly chosen photographs from each plate using National
Institutes of Health (NIH) 1.62 software. Independent an-
chorage growth was assessed in triplicate from two indepen-
dent experiments.
Determination of apoptosis
Apoptotic cells were detected using annexin V/enhanced green
fluorescent protein (EGFP) staining with an ApoAlert Annexin
V-EGFP kit (Clontech, Palo Alto, CA, USA). Stained cells were
quantified using a Becton Dickinson FACScan, and data were
analysed using CellQuest software (version 3.1, Becton
Dickinson).
Animal experiments
Eight-week-old male athymic nude (BALB/c-nu/nu) mice (Clea
Japan Inc, Tokyo, Japan) were maintained under pathogen-
free conditions and used in accordance with NIH and Tohoku
University Medical School institutional guidelines. Logarith-
mically growing cells trypsinized from subconfluent mono-
layers were suspended in medium containing 10% Matrigel
Growth Factor Reduced (Becton Dickinson Labware, Franklin
Lakes, NJ, USA) at a density of 107 cells/mL. Then, 3 × 106 cells
in 300 µL suspension were injected subcutaneously into the
hind flanks of nude mice.
Tumour volume was estimated after biweekly measure-
ments using the formula V = D × d2 × 0.4, where V = tumour
volume, D = largest dimension and d = smallest dimension.
Mice were sacrificed at week 8, when tumours from parental
cells reached approximately 2,000 mm3. Tumours were resected,
weighed and bisected; half of the tissue was snap-frozen in
liquid nitrogen for molecular investigation and the other half
was fixed in neutral buffered formalin for further investigation.
To estimate the metastatic ability of hybrids, we used a
lung colonization model.23 Briefly, parental and hybrid cells
were prepared as single-cell suspensions in sterile phosphate-
buffered saline at a concentration of 5 × 106/mL, then 250 µL
(1.25 × 106 cells, viability 95% as determined by trypan blue
exclusion) was injected intravenously via the tail vein of the
mice. Animals were sacrificed on day 30, when most control
mice became moribund. Surface lung metastatic tumours
were counted and microscopically confirmed. Each hybrid
clone was assessed using two mice, and data from three in-
dependent experiments were pooled for statistical analysis.
No spontaneous mortality or dropouts due to incomplete
tumour growth were recorded.
Immunohistochemical analysis
Sections (5 µm) were prepared from formalin-fixed, paraffin-
embedded specimens. Immunohistochemical reactions were
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performed as described previously,1 using mouse anti-prolif-
erating cell nuclear antigen antibody (anti-PCNA, clone PC10,
Dako Corporation, Copenhagen, Denmark), and developed
using an Immunomouse kit (Zymed Laboratories Inc, South
San Francisco, CA, USA). Proliferating cells were quantitated
by counting PCNA-positive cells as well as total cells in 10
arbitrarily selected fields at × 40 magnification in a double-
blinded manner. The percentage of PCNA-positive cells per
10 × 40 fields was determined from the number of PCNA-
positive cells × 100/total number of cells. Negative control
slides were prepared by omitting the primary antibody.
Statistical analysis
A two-tailed Student’s t test calculated with GraphPad Prism
3.0 software (GraphPad Software Inc, San Diego, CA, USA)
was used to determine the statistical significance of measured
differences. The level of significance was established at p less
than 0.05.
Results
Molecular characterization of parental and hybrid cells
The efficiency of chromosome transfer into hybrids was ex-
plored using microsatellite analysis; typical examples are shown
in Figure 1. A complete copy, or at least a great majority, of
human chromosome 18 was transferred and maintained in
each hybrid cell; the band originating from A9H(18) was seen
in the DNA of each hybrid cell line. To assess whether the
transferred chromosome was maintained indefinitely, we
repeated this analysis at the end of the experiment using sam-
ple DNA from both the hybrids (after 10–15 passages) and sub-
cutaneous tumours generated in nude mice (Figure 1). The
results confirmed that the additional copy of chromosome 18
was efficiently transferred and maintained indefinitely.
Phenotypic assessments
In vitro growth of hybrid cells was significantly suppressed
compared with parental cells, regardless of initial SMAD4
status (Figure 2). No morphological changes were apparent
throughout the hybrid clones when compared with either
parental or control cells (Figures 2B and C). This suggests that
a product of a chromosome 18 gene other than SMAD4 plays
a role in this behaviour of hybrids cells.
To study proliferation and morphology under anchorage-
independent conditions, we transferred both parental and hy-
brid cells from a mono- to a bi-layered Bacto-agar suspension.
The size and number of colonies observed among hybrids were
significantly smaller than among parental cells (mean, 49 ±
3.6 vs 228 ± 19.36 colonies/wheel and 106 ± 19.61 vs 392 ±
37.22 µm for PK-1H(18) and PK-1, respectively). In addition,
parental cells formed tight, densely packed, multicellular sphe-
roids (MCS) easily detected by the naked eye, while hybrids
formed smaller, loose spheroids (Figures 2D and E). Because
the ability of cells to grow in soft agar suspension very closely
correlates with their tumorigenic potential in vivo,24 these
features strongly suggest that chromosome 18 transfer is
associated with major changes in hybrid cell behaviour.
The percentage of annexin V-positive parental cells (2.1 ±
0.5%) was very low (Table); the percentage increased slightly
among hybrid clones (3.9 ± 0.7%). Thus, apoptosis is unlikely
to participate in the chromosome 18-mediated growth sup-
pression observed in hybrid cells.
Despite inherent interclonal variation, the hybrids showed
a significant reduction in tumour volume and a longer latency
compared to parental cells (Figures 3A–D). We found that 16%
of tumour cells stained positive for PCNA in hybrid tumours
compared with 57% in parental tumours (Figures 3E and F).
Thus, proliferation was decreased in hybrid tumours com-
pared with parental tumours (Table), indicating that retarda-
tion of tumour growth is caused by diminished proliferation
of hybrid cells.
The number of surface metastases in mice lungs injected
with hybrids was significantly decreased compared with that
in mice injected with parental cells (Table). Furthermore,
Figure 1. Microsatellite analysis. Representa-
tive scanned autoradiographs showing resto-
ration of heterozygosity for the different 18q-
microsatellite markers after chromosome 18
transfer into PK-1 cells. Arrows indicate new
bands of the same size as those obtained from
A9H(18)H used as donor cells. The generic
names and cytogenetic position (Genome
Database, http://gdbwww.gdb.org) along 18q
are indicated below every panel. P = parental
cells; H = hybrids; T = nude mouse tumours.
D18S1104
(48.9 cM)
D18S463
(56.6 cM)
D18S1144
(80.2 cM)
D18S483
(96.9 cM)
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Figure 2. In vitro proliferation. A) 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays indicated that hy-
brids (dashed lines) derived from SMAD4wt cells demonstrated the
ability to suppress in vitro growth to a greater extent than hybrids
derived from SMAD4–/– recipients (*p < 0.05). Note the same trend
for parental cells. The calculated standard deviations (bars) were
too low to be resolved in some curves. Up-to-down arrows reflect
mean differences recorded between hybrid and parental cell tumours.
B, C) PK-1 parental cells and their hybrids at 96 hours under a
phase-contrast microscope at original magnification × 20. D, E) An-
chorage-independent growth at day 21 shows that hybrids have
an increased ability to suppress growth in soft agar (D, PK-1; E, PK-
1H(18)). Bar = 500 µm.
lungs showing no metastases at surface examination had few
detectable micro-metastases; some of them appeared to be
dormant. These results demonstrate that the introduced chro-
mosome 18 provides an important factor that reduces meta-
static activity.
Discussion
Pancreatic cancer, like other cancers, is a genetic disease aris-
ing from an accumulation of mutations that promote clonal
selection of cells with increasingly aggressive behaviour.25 At
the time of the initial detection of clinical cancer, several
genetic alterations have already accumulated in tumour cells.
In pancreatic cancer, KRAS, TP53, p16 and SMAD4 are thought
to play key roles in tumorigenesis.26 Several lines of accumu-
lated evidence have clearly shown that loss of 18q is one of
the more consistent findings among chromosomal abnormali-
ties identified in a variety of cancers, and that this event is asso-
ciated with a poor clinical outcome.5 However, functional evi-
dence implicating chromosome 18 in pancreatic tumorigene-
sis is desirable.
In this study, we used MMCT to introduce a normal copy
of human chromosome 18 individually into two pancreatic
cancer cell lines. MMCT is a useful tool that has provided
functional evidence of the location of tumour suppressor
genes in a variety of cancers including melanoma27 and pros-
tate cancer.28 We first performed MMCT and then checked the
efficiency of chromosome transfer by microsatellite analyses.
Although corresponding normal tissues were not available for
each cell line, we demonstrated the introduced chromosome
18 by observing the additional band in hybrid cells. Because
these cell lines do not have high microsatellite instability,29
additional bands for each marker are likely to be derived from
the introduced 18q copy. Although some microdeletions can-
not be totally excluded, it is reasonable to assume that the
great majority of the 18q arm was maintained in our hybrid
cells. However, in this system, based on a semi-quantitative
PCR method, it is impossible to estimate the percentage of
cells retaining the transferred chromosome copy.28
In vitro growth of the hybrid clones was significantly de-
layed compared to that of parental cells, apparently regardless
of initial SMAD4 status. The latter fact is not surprising since
over-expression of SMAD4 itself does not affect the in vitro
proliferative rate of pancreatic cancer cells.8 The in vitro culture
of cells in suspension is believed to more closely mimic in vivo
conditions than the culture of cells in a two-dimensional
monolayer.24 The size and number of colonies were signifi-
cantly smaller among hybrids than among parental cells. In
addition, parental cells formed tight, densely packed MCS
easily detected by the naked eye, while hybrids formed smaller,
loose spheroids. This is in keeping with changes in the adhe-
sion properties of hybrids, but should be examined in the light
of further specific investigation. The ability of cells to grow in
soft agar suspension very closely correlates with their tumori-
genic potential in vivo, so the results of this experiment showed
that chromosome 18 transfer is associated with major changes
in tumour cell behaviour.
Cells undergoing apoptosis were detected using an annexin
V assay, which measures phospholipid turnover from the in-
ner to the outer lipid layer of the plasma membrane, an event
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typically associated with apoptosis. In comparison with tra-
ditional tests, this assay is sensitive and offers the possibility
of detecting early phases of apoptosis before the loss of cell-
membrane integrity, and permits measurement of the kinetics
of apoptotic death in relation to the cell cycle.30 The percent-
ages of annexin V-positive cells were very low in parental cells
and slightly increased among the hybrid clones (Table). Thus,
apoptosis is unlikely to be involved in chromosome 18-medi-
ated growth suppression observed throughout the hybrid
clones.
Tumorigenesis in nude mice is one of the most stringent
tests and yields highly valuable information about cancer-cell
behaviour. In order to shorten tumour latency and enhance
tumour growth, we mixed cells in a suspension containing
Matrigel extract. Despite inherent interclonal variation, hy-
brids showed a significant reduction in tumour volume and a
longer latency compared to parental cells. Remarkably, there
was a significant difference in tumour volumes related to
SMAD4 status. Specifically, SMAD4+/+ cells generated signifi-
cantly bigger tumours with a shorter latency than SMAD4–/–
cells. This has recently been explained by the fact that SMAD4
inhibits angiogenesis via putative down-regulation of
vascular endothelial growth factor.8 We found that 16% of
tumour cells stained positive for PCNA in hybrid tumours
compared with 57% in parental tumours. Thus, proliferation
was decreased in hybrid tumours compared with parental
tumours (Table), which indicated that retardation of tumour
growth is caused mainly by slower proliferation.
Metastasis-regulatory genes can be broadly categorized as
either metastasis-promoting or metastasis-suppressing. Anal-
ogous to the role of oncogenes in tumorigenesis, metastasis
promoters drive conversion from non-metastatic to meta-
static cells.31 As expected, tumour suppressors inhibit both phe-
notypes because tumorigenicity is a prerequisite for metas-
Figure 3. In vivo growth. A–D) Significant
suppression of tumorigenesis in hybrids
compared to parental cells. Each point
reflects the average of three tumours from
two different experiments. Up-to-down
bars reflect mean differences recorded be-
tween hybrid and parental cell tumours.
Calculated standard deviations (bars)
were too low to be resolved in some curves
(*p < 0.001). In A and C, the up-to-down
arrows reflect the latency period for hybrid
(open arrows) and parental cell tumours.
E, F) Decreasing proliferation index in hy-
brid xenografts. Percentage of proliferat-
ing cell nuclear antigen-positive cells per
10 arbitrarily selected fields at × 40 mag-
nification (E, PK-1; F, PK-1H(18)).
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tasis.32 As chromosome 18 harbours a cluster of candidate
tumour and metastasis suppressor genes, i.e. SMAD2, SMAD4,
DCC, maspin and PAI-2, and because poor prognosis is signifi-
cantly associated with 18q-LOH,5 it is of great interest to
examine whether genes on chromosome 18 play roles in meta-
static processes. To estimate the metastatic ability of hybrids,
we used a lung colonization model. We recorded a significant
suppression in the number of surface metastases in mice
injected with hybrids compared to mice injected with parental
cells (mean, 5 vs 51 for PK-1(18) and PK-1, respectively) (Table).
This demonstrated that 18q encodes an important metastasis
suppressor factor and confirmed our previous study that
clearly correlated LOH of 18q with poor prognosis in patients
with pancreatic cancer.5
The MMCT technique means that hybrid cells usually do
not contain mouse chromosomes,19 but there is nevertheless
a small possibility that the observed growth suppression could
be attributed to the effects of remaining mouse chromosomes.
However, we obtained three independent hybrid clones for
each parental cell line, and the possibility that these individual
clones would harbour the same particular undetected mouse
chromosome or chromosome fragments is unlikely. Hence, it
is likely that the tumour suppression phenotype is caused by
the introduction of normal human chromosome 18 into pan-
creatic cancer cells.
Nevertheless, whole chromosome transfer raises at least
two issues: the direct effects of known or unknown genes
located on chromosome 18, and indirect effects through pos-
sible interactions among the transferred chromosome and
other genes. Although in this setting, these effects could not
be clearly delineated, it is conceivable that introduction of
an extra copy of chromosome 18 confers a less aggressive tu-
mour phenotype on pancreatic cancer cells. In other words,
the metastatic inhibition encoded by 18q could explain the
dormant status of the hybrids and, in turn, the presence of
micro-metastases unable to form macro-metastases. Although
this study clearly implicates the important role of gene(s) on
chromosome 18, the precise sub-chromosomal localization of
the metastasis suppressor gene(s) remains an open question.
In the absence of spontaneous revertant hybrids, the precise
localization and identification of a putative metastasis sup-
pressor gene will require further effort. In an attempt to define
new presumable interactions between genes on chromosome
18 and others, a microarray analysis is currently under way in
our department.
Briefly, we achieved significant suppression of both in vitro
and in vivo growth of pancreatic cancer cells by transfer of
chromosome 18. The suppression was observed regardless of
SMAD4 status, and induction and restoration of SMAD4 could
not prevent in vitro growth, regardless of SMAD4 mutational
background.8 These functional data bring into sharp relief the
implication of chromosome 18 in pancreatic carcinogenesis,
but new research will be able to locate tumour suppressor
gene(s) in this region.
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